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Abstract
Glomerulosclerosis is a common pathologic finding that often progresses to renal failure. The
mechanisms of chronic kidney disease progression are not well-defined but may include activation
of numerous vasoactive and inflammatory pathways. We hypothesized that podocytes are
susceptible to filtered plasma components including hormones and growth factors that stimulate
signaling pathways leading to glomerulosclerosis. Gα12 couples to numerous G-protein-coupled
receptors (GPCR) and regulates multiple epithelial responses including proliferation, apoptosis,
permeability and the actin cytoskeleton. Herein, we report that genetic activation of Gα12 in
podocytes leads to time dependent increases in proteinuria and glomerulosclerosis. To mimic
activation of Gα12-pathways, constitutively active Gα12(QL) was conditionally expressed in
podocytes using Nphs2-Cre and LacZfloxed QLα12 transgenic mice. Some QLα12LacZ+/Cre+
mice developed proteinuria at 4-6m, and most were proteinuric by 12m. Proteinuria increased with
age, and by 12-14m many demonstrated glomerulosclerosis with ultrastructural changes including
foot process fusion and both mesangial and subendothelial deposits. QLα12LacZ+/Cre+ mice
showed no changes in podocyte number, apoptosis, proliferation, or Rho/Src activation. Real-time
PCR revealed no significant changes in Nphs1, Nphs2, Cd2ap, or Trpc6 expression, but Col4a2
message was increased in younger and older mice while Col4a5 was decreased in older mice.
Confocal microscopy revealed disordered collagen IVα1/2 staining in older mice and loss of α5
without changes in other collagen IV subunits. Taken together, these studies suggest that Gα12
activation promotes glomerular injury without podocyte depletion through a novel mechanism
regulating collagen (α)IV expression, and supports the notion that glomerular damage may accrue
through persistent GPCR activation in podocytes.
Glomerulosclerosis (GS) is a common pathologic finding in patients with progressive
chronic kidney disease (CKD) and often leads to end stage renal disease (ESRD). Numerous
conditions predispose patients to GS including diabetes, hypertension, IgA nephropathy,
FSGS (focal segmental GS) and immune-mediated injury. In adults over 60 years-old, the
prevalence of CKD Stage III (glomerular filtration rate, 30-59mL/min) is estimated to be
>25% (1). Although risk factors such as hypertension and diabetes are linked to CKD, little
is known about the signaling mechanisms that lead to progression with ageing. Post mortem
and nephrectomy samples in otherwise “healthy“ adults reveal variable amounts of
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tglomerulosclerosis and interstitial fibrosis, suggestive of age associated damage (2, 3).
Recent studies show that primary podocyte injury is sufficient to induce GS (4, 5).
Podocytes are exposed to filtered reactive oxygen species (ROS), lipid mediators, cytokines
and hormones that could contribute to injury. Many of these molecules activate G protein-
coupled-receptors (GPCR), which couple to multiple Gα subunits. Each of the 16 Gα
subunits (four main families; Gαs, Gαi/o, Gαq and Gα12/13) couples to many different
GPCRs (6); thus, defining specific pathways in vivo has been difficult.
Gα12/13 are expressed in podocytes and couple to angiotensin II (AII), thrombin,
endothelin, and LPA receptors, that are important in renal injury (7). Gα12/13 can activate
Rho or Src to regulate the actin cytoskeleton (8), in addition to proliferation, transformation
(9), tight junction (TJ) assembly (10-12), cell-cell adhesion (13, 14), directed cell migration
(15), apoptosis (16), and cell attachment (17). RhoGDIα knockout mice develop proteinuria
and renal failure (18), and many mutations in hereditary FSGS affect proteins linked to the
actin cytoskeleton (reviewed in (19)). Gα12 also upregulates TGFβ (20, 21) and, several
gene profiling studies found upregulated Gα12 in proteinuric kidneys and post transplant
CKD (via Nephromine (22, 23)).
Targeting activated Gα subunits to specific cells in vivo permits identification of
downstream effector pathways independent of receptor activation and thus, permits insight
in to disease mechanisms otherwise impossible to study in vivo. Herein, we confirm
expression of endogenous Gα12 in the major podocyte processes. Constitutively activated
Gα12 (QLα12) was expressed in podocytes using a transgenic model that results in mosaic
expression and mimics the focal nature of GS pathology. QLα12LacZ+/Cre+ mice develop
proteinuria and focal GS without differences in podocyte number, apoptosis, proliferation,
or Rho/Src signaling over time. Col4a was disregulated and correlated with altered
localization and ultrastructural changes. These findings indicate that Gα12 activation in
podocytes leads to disregulated collagen α(IV) expression, and supports a model of altered
glomerular structure and function resulting from time dependent stimulation of GPCR-Gα12
signaling pathways.
Methods
Transgenic Mice Creation
All animal procedures were performed in accordance with the guidelines of the Institutional
Animal Care and Use Committee at Harvard University. Gα12 (Q229L) EE tagged was
cloned in to the CMV floxed LacZ cassette kindly provided by Dr. Larry Holzman (24).
C57/B6 mice were injected at the Brigham and Women’s Hospital Transgenic Mouse
Facility and were then crossed with Nphs2/Cre mice on the same C57/BL6 background.
Urine Microalbumin, Serum Creatinine, LPS and Tissue Harvesting
Male and female mice were analyzed for urine microalbumin/creatinine ratio at specified
ages using Bayer DCA 200+ Analyzer with software version E3.11/01.04. Mice were
defined as proteinuric when microalbumin/creatinine ratio ≥34 due to the detection limits of
the analyzer. LPS (Invivogen, San Diego, CA) (IP 10μg/g) was administered to 2-6m old
mice, and urine was collected 18h post-injection and microalbumin/creatinine ratio. Serum
was collected and BUN and creatinine analyzed using an iStat System with CHEM8+
catridges. Mice were anesthetized using inhaled isofluorane (Phoenix Pharmaceuticals, St.
Louis, MO). For whole kidney collection, organs were perfused with cold PBS. Kidneys
were removed and processed according to methods below.
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The GST-TPR construct was kindly provided by Dr. M. Negishi, Kyoto University, Kyoto
Japan. GST-TPR was prepared as described previously (16). Harvested kidneys were
homogenized in lysis buffer with eComplete (Roche) protease inhibitors, lysed through 22G
needle and normalized for protein concentration. 1 μg of GST-TPR coupled to glutathione-
agarose beads (Amersham Biosciences) was added to 800 μg of total protein and rocked
overnight at 4 °C. Beads were pelleted with low speed centrifugation and washed three times
with PBS, 0.1% Triton X-100, resuspended in Laemmli sample buffer, and analyzed by
SDS-PAGE and Western blot using a Gα12 antibody (Santa Cruz, Santa Cruz, CA).
Immunogold EM
Immunogold labeling and EM was performed at the Membrane Biology Program,
Massachusetts General Hospital. Normal mouse kidney was fixed in 2% fresh-made
paraformaldehyde and 0.5% glutaraldehyde in 0.1M phosphate buffer, pH 7.4 and processed
according to standard conditions. Grids were incubated with Rabbit anti-Gα12 (Santa Cruz)
overnight at 4°C followed by a 25μl droplet of anti-goat IgG conjugated with gold (10nm).
Grids were washed and imaged using Philips CM10 electron microscope (Philips
Electronics, Mahwah, NJ).
Histology
Fixed kidney tissue was paraffin-processed and 4μm sections were stained with PAS. Light
microscopic evaluation included quantification of the total number of glomeruli present in
one microscopic section as well as quantification of glomeruli with lesions (global sclerosis,
segmental sclerosis, glomerular collapse, and glomerular hypertrophy).
Electron microscopy
Fixed specimens were trimmed, post-fixed with osmium tetroxide, dehydrated in serial
ethanols, and embedded in epoxy resin. Ultrathin sections were cut at 80nm, mounted on
200 mesh copper grids, treated with uranyl acetate and lead citrate, and examined in a JEOL
1010 transmission electron microscope (Tokyo, Japan). Electron micrographs showing
glomerular ultrastructure were analyzed in a blinded manner. Podocytes, endothelium,
GBM, and mesangium were examined and scored from 0 (no abnormality) to 4 (severe
abnormality). Podocytes were scored for foot process effacement and irregularity,
microvillous degeneration, vacuolization, and subepithelial deposits. Endothelium was
scored for: double contours, subendothelial deposits, and swelling. GBM abnormalities were
scored for thickness and irregularity, and the mesangium was scored for deposits, expansion
by matrix, and cellular expansion.
LacZ, TUNEL, and Immunostaining
Fixed kidneys were washed in PBS and rehydrated overnight in 30% sucrose. Kidneys were
embedded in O.C.T Compound (TissueTek, Sakura Finetek, Torrence, CA) and frozen in
liquid nitrogen. For WT-1 and TUNEL staining, sections were labeled using the “In Situ
Cell Death Detection Kit” (Roche) according to the manufacturers protocol. Kidneys were
incubated in methanol, blocked, and incubated in anti-WT-1 antibody (sc-192/Santa Cruz) at
4°C overnight. Sections were washed, incubated with appropriate secondary antibody, and
mounted using Prolong Gold (Invitrogen). Kidneys were photographed on a Nikon E-1000
equipped with a SPOT digital camera. For collagen staining, kidneys were blocked in 1%
BSA, and incubated with primary antibodies (generous gift of D.B. Borga, Vanderbilt) or
(Rockland Gilbertsville, PA). All sections were incubated with appropriate secondary
antibody for 1hr at room temperature, and mounted using Prolong Gold (Invitrogen). Images
were taken on a Nikon C1 D-Eclipse confocal microscope.
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Glomerular isolation was performed using magnetic beads(25). Two hundred μL Dynabeads
(M450 Tosylactivated, Invitrogen, Carlsbad, CA) were washed with 0.1% PBS and
incubated overnight in 0.2M Tris pH8.5 with 0.1%BSA. Beads were washed and
resuspended in 30mL HBSS. Mice were anesthetized and organs perfused with HBSS.
Kidneys were digested in 1mg/ml collagenase A (Roche, Indianapolis, IN) and 100u/ml
DNaseI (New England Biolabs, Ipswich, MA) at 37°C for 30min. Digests were strained
though a 100μm cell strainer, centrifuged and resuspended in HBSS. Glomeruli were
obtained using magnetic separator (New England Bio Labs, Ipswich, MA).
RhoA Activation ELISA and Western Blot
Isolated glomeruli were resuspended in lysis buffer with eComplete (Roche) protease
inhibitors and lysed through 22G needle. Rho activity was determined using G-LISA™
RhoA Activation Assay Kit (Cytoskeleton Denver CO) and absorbance at 490nm of an
HRP-active RhoA antibody. Additionally, samples were analyzed by SDS-PAGE and
Western blot analysis using an anti-RhoA antibody (Cytoskeleton) as previously described
(17).
Real Time PCR
Purified glomeruli were lysed in TRIzol reagent (Invitrogen). RNA concentrations were
determined, and RNA was incubated in DNAse I (New England Biolabs) with RNAse
Inhibitor (Roche). DNAse treated RNA was reverse transcribed using Transcriptor Reverse
Transcriptase (Roche). Negative control without enzyme was included in each analysis. The
cDNA template was treated with RNaseH (Invitrogen). TaqMan Gene Expression assays
(Applied Biosystems Foster City, CA) were performed using an ABI 7300 (Applied
Biosystems) with the following conditions: 2min at 50°C and 10 min at 95°C, followed by
50 cycles of 95°C for 15s and 60°C for 1min. Melting curve analysis and gel electrophoresis
of PCR products verified that a single product of the expected size was generated with each
primer set. Data analysis used the ΔΔCt method. Ct was normalized to 18S ribosomal
subunit.
Statistical Analyses
Data are expressed as medians or means ± SEM as indicated. Statistical analysis was
performed using Prism 4 for Macintosh (GraphPad La Jolla, CA) using two-way ANOVA
followed by Bonferroni’s post hoc test. Statistical significance was identified at P < 0.05.
Results
Gα12 is Expressed in Glomeruli
Although Gα12 is expressed in proximal and distal tubular epithelial cells (26) and
glomerular proteomics identified Gα12 (27), its localization in glomeruli has not been
described. Endogenous Gα12 was localized in normal mouse glomeruli by
immunohistochemistry. At lower power, Gα12 was detected in glomeruli (Figure 1A; arrow
heads) and throughout the nephron. At higher power (Figure 1A, black/white arrows),
several cell types including podocytes, appear to express Gα12 with only background
staining in the controls (antibody preincubated with peptide) (Figure 1A, b, d). To confirm
podocyte Gα12 localization, immunogold electron microscopy (EM) was performed (Figure
1B). Gold particles were visible in several locations including foot processes (FP), major
processes (MP), and at the branch points proximal to the foot processes (arrows). The
localization of Gα12 in major processes suggests that Gα12 may have functions not directly
related to slit diaphragm permeability.
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Mice expressing EE tagged, human Gα12 (Q229L) were established using a LacZ/floxed
transgenic approach ((24), Figure 2A). For conditional expression (28), QLα12LacZ+/Cre-
mice were crossed with Nphs2-Cre mice, (Nphs2 is efficiently expressed in podocytes and
no other glomerular cells, (29) Cre-mediated excision of the LacZ/stop in podocytes resulted
in QLα12 expression (QLα12LacZ+/Cre+) (Figure 2). The CMV promoter is associated
mosaic expression due to random inactivation (24) although Cre efficiently excises LacZ in
these podocytes. QLα12LacZ+/Cre- (Control) and QLα12LacZ+/Cre+ mice at 2m of age
(littermates) were stained for β-Gal using standard techniques. β-gal staining revealed that
transgene expression was low in proximal tubules, but higher in the papilla [as reported (24),
not shown]. QLα12LacZ+/Cre+ mice showed a major reduction in glomerular LacZ staining
(Figure 2B) compared with Cre- controls. A semi-quantitative analysis of β-gal staining
suggested that random inactivation of the CMV promoter in podocytes led to LacZ
expression in approximately half of the targeted cells (Supplemental Figure 1). Note that all
the Cre+ mice showed significantly less or no β-Gal staining while the controls were evenly
distributed (Supplemental Figure 1). The small amount of residual LacZ staining in
QLα12LacZ+/Cre+ mice likely reflects LacZ expression in mesangial or endothelial cells. To
distinguish EE-QLα12 expression from endogenous Gα12, control and QLα12LacZ+/Cre+
kidneys were co-stained with anti-nephrin and anti-EE antibodies (Figure 2C). In control
mice, nephrin was seen throughout the glomerulus, with no detectable EE staining (Figure.
2C, a). In QLα12LacZ+/Cre+ mice, both proteins were detected (Figure 2C, b), and as
expected from immunoEM (Figure 1B), there was little overlap with nephrin in the slit
diaphragm. ImmunoEM using the EE epitope antibodies confirmed transgenic QLα12
expression (not shown) in a similar distribution to the endogenous Gα12 (Figure 1B). To
confirm that active Gα12 was expressed in these glomeruli, GST-TPR pulldowns were
performed as previously described (16); the TPR domain of PP5 binds the active
conformation of Gα12/13 (30). Figure 2D shows GST-TPR pulldowns of thrombin
stimulated MDCK cells compared with cortical kidney lysates from QLα12LacZ+/Cre+ and
QLα12LacZ+/Cre- mice.
QLα12 Expressed in Podocytes Leads to Age-Dependent Proteinuria
Development of microalbuminuria is a sensitive marker for podocyte injury (31). Urine was
analyzed for albumin/creatinine ratio (Figure 3A) from QLα12LacZ+/Cre+ and control mice
every two months. Microalbuminuria (albumin/creatinine ratios ≥34) appeared in a few
control mice at 4-6m but was seen in ~40% of QLα12LacZ+/Cre+ mice (some with ratio
>200, Figure 3, Table 1). Most the QLα12LacZ+/Cre+ mice developed proteinuria as they
aged while only a few controls had mildly increased levels. Coomassie blue staining of urine
confirmed the expression of albumin (Figure 3B). The magnitude of proteinuria continued to
increase until sacrifice at 22-26m. Based on this phenotype, we divided the mice into young
(<6m; occasional mild proteinuria) and older (>12m; frequent and often severe proteinuria)
for further analysis.
The lack of proteinuria in most younger mice suggests that podocytes compensate for the
expression of activated Gα12. To test whether QLα12 expression predisposed younger mice
(<6m) to injury, proteinuria was examined after LPS stimulation (a model of transient
podocyte injury) (Figure 3C)(32). Baseline proteinuria was similar, and 18h after LPS
stimulation, control mice increased proteinuria 1.9-fold, while QLα12LacZ+/Cre+ mice
showed a significantly larger increase (3.6-fold). However, these short-term experiments did
not detect any differences in ultrastructural or light microscopy findings (not shown). These
findings are consistent with LPS-stimulated podocyte actin cytoskeleton changes leading to
proteinuria and reveal that podocyte expression of QLα12 in young mice enhances the
injury response.
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tFocal GS Develops with Age in QLα12LacZ+/Cre+ Mice
In mice aged <6m, no significant renal histopathologic changes were observed in control or
QLα12LacZ+/Cre+ mice (Figure, 4 A, E). However, by 12-18m, QLα12LacZ+/Cre+ mice
showed numerous globally and segmentally sclerosed glomeruli while controls exhibited
only rare sclerosed glomeruli. Quantifying affected glomeruli showed a >6-fold increase in
sclerosed glomeruli from kidneys of QLα12LacZ+/Cre+ mice (n=7) compared with controls
(n=7) (B, F). Segmentally sclerosed glomeruli were characterized by hyalinosis, glomerular
basement membrane (GBM) reduplication, isolated epithelial cells containing PAS-positive
protein reabsorption granules, and adhesion of the tuft to Bowman’s capsule. Mesangial
areas of QLα12LacZ+/Cre+ mice exhibited mild to focally moderate expansion by matrix and
cells, whereas the mesangial areas of control mice exhibited minimal expansion (B, F,
arrow). The kidneys of 18m mice exhibited changes similar to the 12-18m group, but more
prominent. On average, 4.79% of glomeruli in QLα12LacZ+/Cre+ mice were globally or
segmentally sclerosed, whereas only 0.16% of glomeruli in control mice were sclerosed
(Figure 4 C, D, E, H,). Over 73% of these sclerosed glomeruli were juxtamedullary. Focal
segmental double contours (areas of GBM redundancy) were more commonly seen in
QLα12LacZ+/Cre+ mice than in controls. Occasional PAS-positive hyaline casts were
observed in the medulla to varying degrees in older animals as well as focal interstitial
mononuclear inflammation, usually in association with focal GS. (Figure 4 G, H arrows).
Features of focal tubular injury, including tubular luminal distension, epithelial flattening,
and microcyst formation, were seen in a subset of the oldest QLα12LacZ+/Cre+ mice and
these findings were not seen in the age matched controls. The non-lesional glomeruli (H;
arrowhead) exhibit moderate mesangial expansion by matrix and cells (*). Other features of
active or chronic tubulointerstitial or vascular pathology were not observed in any animals.
There were no detectable differences in serum creatinine between the 14-19 month old
QLα12LacZ+/Cre+ mice and controls as all values were ≤0.2 mg/dL.
Older QLα12LacZ+/Cre+ Mice Develop GBM Irregularities, Mesangial Expansion and Foot
Process Fusion
EM of QLα12LacZ+/Cre+ and control mice <6m, 12-18m and >18m were scored for
ultrastructural abnormalities. The youngest QLα12LacZ+/Cre+ mice (Figure 5A) appeared
normal. At 12-18m, there was little difference in the GBM or the podocytes, but most
QLα12LacZ+/Cre+ mice had focal features of endothelial injury including double contours,
subendothelial granular electron dense deposits, and cell swelling (Figure 5E arrowhead; not
seen in the controls). Additionally, QLα12LacZ+/Cre+ scored higher for mesangial expansion
by matrix and cells (Figure 5E,*; Table 2). Older QLα12LacZ+/Cre+ mice (>18m) (Figure 5F)
mice exhibited a greater degree of foot process effacement and irregularity presumably
associated with aging (Figure 5F, arrows) than was seen in the controls (although controls
did reveal some age-related changes). There were few differences in the GBM, but there
were an increased number of subepithelial GBM membrane projections in the oldest
transgenics (Figure 5F, ◆). All mice exhibited mild mesangial expansion at >18m; however
QLα12LacZ+/Cre+ mice showed more severe signs of mesangial abnormalities (Figure 5F, *),
and overall scores (Table 2) for glomerular injury were twice as high in the
QLα12LacZ+/Cre+ mice (Figure 5C).
QLα12LacZ+/Cre+ Mice Have Normal Numbers of Podocytes
Based on the morphologic changes, we examined podocyte number by Wilms’s Tumor-1
(WT-1) staining (33). Surprisingly, podocyte number/glomerulus showed no difference
between QLα12LacZ+/Cre+ and controls >12m (Figure 6A, B). As Gα12 can stimulate both
proliferation and apoptosis (16), WT-1 positive cells were quantified for apoptosis (TUNEL)
and proliferation (Ki67) to exclude the possibility that podocyte number was preserved
through QLα12 costimulation of proliferation and apoptosis. No apoptotic podocytes were
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tseen in either QLα12LacZ+/Cre+ or controls (Figure 6A, middle panels), nor any difference
observed in proliferation (not shown). Additionally, there were no differences in the number
of glomeruli in kidneys obtained from QLα12 LacZ+/Cre+ mice as compared to controls (data
not shown). This indicates that development of proteinuria and glomerulosclerosis does not
result from developmental effects on glomeruli number or podocyte depletion, and other
mechanisms must be responsible.
QLα12 Expression in Podocytes Does Not Lead to Rho or Src Activation
Next, Rho activity was examined in QLα12Lac+/Cre+ and control mice. Rho activity was
determined by ELISA on glomerular isolates from young and old mice. There were no
significant differences in Rho activity from QLα12Lac+/Cre+ mice compared with controls,
nor was there any difference in Rho protein expression (Figure 7A). Gα12 also activates Src
(34), and Western blot using pY419 antibodies failed to demonstrate any differences in Src
activation (not shown). This finding suggests that podocytes compensate for persistent
QLα12 expression and employ other mechanisms to prevent sustained Rho or Src
activation.
Real Time PCR Showed No Changes in Podocyte Specific Genes, but QLα12LacZ+/Cre+ Mice
Exhibit Disregulated Glomerular Collagen Expression
Real time PCR of glomerular isolates failed to detect changes in expression levels of several
major podocyte genes implicated in FSGS (Nphs1, Nphs2, CD2AP, and TRPC6)
(Supplemental Figure 2). The normal adult GBM is composed predominantly of α3, α4 and
α5(IV) collagen and laminin-11 (α5β2γ1)(35). During development, the normal GBM is
composed of α1 and α2(IV) collagen that is followed by a switch to α3, α4 and α5(IV)
expression in mature glomeruli. Real time PCR of Col4a showed increased Col4a2 transcript
expression levels in younger mice (Figure 8A) although the variability in phenotype led to
wide confidence intervals. These age-dependent changes are likely to contribute to the
observed variability and since this analysis was performed on isolated glomeruli, it is
possible that the most severely sclerotic glomeruli were not included and would thus tend to
underestimate the differences. In addition, the real time results were reanalyzed in male and
female mice, and no differences were observed to account for the differences in phenotype
seen between transgenic and control mice in any age group (not shown). Nevertheless, when
considered together, these results suggest a change in the relative balance of specific
collagen α(IV) chains, and immunofluorescence microscopy confirmed mildly increased
collagen α1/2(IV) expression (Figure 8C). In older mice, Col4a2 expression abnormalities
persist and by 12-14m there is also a 2-fold increase in Col4a1 and decreased Col4a5
(Figure 8C). Consistent with the real-time results, collagen α1/2(IV) staining was increased
in older mice, and the localization was disorganized without clear capillary loop staining
(Figure 8D). Decreased expression of α5 was confirmed although the pattern of staining
appeared similar to the control (Figure 8D). No other α(IV) chains showed differences in
staining. The α3/4/5 antibody showed decreased intensity compared with the control and
based on the α3 staining and real-time results, this difference is most likely explained by the
decreased α5 collagen expression. To determine if QLα12 directly regulates Col4 gene
expression, a previously characterized inducible (tet off) QLα12-MDCK cell line (10, 11,
17) was analyzed by microarray. Supplemental Figure 3 shows 7 and 10 fold increase in
Col4a1 and Col4a2 respectively within 72h of QLα12 expression. Taken together, this
analysis indicates that QLα12 expression leads to disregulated Col4a gene expression prior
to the onset of proteinuria and suggests a mechanism where activated Gα12 alters Col4 gene
expression.
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Understanding the mechanisms of CKD progression is important for finding new therapeutic
targets. Podocytes are exposed to approximately 180L of ultrafiltrate/day that contains
biologically active molecules, including hormones, cytokines, and filtered proteins. Herein,
we demonstrate that activation of Gα12 in podocytes leads to age-dependent proteinuria and
focal GS through a distinct mechanism involving disregulated collagen α(IV) expression
without podocyte depletion. This supports the hypothesis that filtered agonists activate
podocyte signaling pathways and can contribute to progressive glomerular injury. Although
Gα12 regulates numerous processes that could lead to podocyte damage including
apoptosis, proliferation, cell attachment, actin cytoskeletal changes, and junctional
regulation, these do not explain the time-dependent phenotype in these mice. Rather, a novel
mechanism of collagen α(IV) abnormalities appears to be responsible.
Testing the notion that podocytes respond to filtered molecules is difficult to examine in
vivo. Expressing a constitutively active G-protein allows for identification of downstream
effector pathways, and this approach led to the identification of h-Ras as an oncogene (36).
This strategy could identify novel therapeutic targets to prevent GS without the need to
identify the specific GPCR or its ligand. Analogous to our studies, activated (QL) Gαq was
targeted to podocytes (37) and these mice developed proteinuria through a different
mechanism. QLαq mice had developmental defects including smaller kidneys and reduced
nephron number. There was downregulation of nephrin and other podocyte genes although
Col4a was not examined. QLαq mice were more susceptible to puromycin aminonucleoside
injury, and a subset of mice developed GS at 6m of age, a finding that could occur from
reduced nephron number. In contrast, QLα12 in podocytes did not affect renal development,
nephron, or podocyte number and revealed altered regulation of collagen and GBM
abnormalities.
Proteinuria developed in some QLα12LacZ+/Cre+ mice by 4-6m, prior to morphologic
changes (Figures 3-5). By 12-14m, there was some foot process fusion that could account
for the increased in proteinuria; however, the CMV promoter results in mosaic expression,
and we estimate that only about half of podocytes express QLα12 (Figure 2). This focal
expression is likely to account for the mild phenotype, but also recapitulates local
differences in glomerular response to stress and the focal nature of GS. In fact, the majority
of sclerotic glomeruli were located at the cortico-medullary junction, a region where
glomeruli are more susceptible to hemodynamic stress (38, 39). Why some younger mice
manifest proteinuria before morphologic changes are detected is not clear. They do not show
enhanced baseline Rho or Src activity, but they are more susceptible to LPS induced
proteinuria (without changes in Col4 gene expression (not shown), suggesting that QLα12
can promote functional effects on permeability. The absence of ultrastructural changes in
young mice or after LPS suggests that perhaps through Gα12 localization in the major foot
processes, it regulates cortical actin and permeability. Although only about 5% of the
glomeruli develop GS, proteinuria is likely to arise from a more global effect on
significantly more glomeruli. This is based on the observation that QLα12 is expressed in
approximately 50% of glomeruli (Supplemental Fig. 1) and QLα12 expression increased
proteinuria in LPS treated mice without morphologic or ultrastructural changes.
Mesangial expansion was prominent in the QLα12LacZ+/Cre+ mice, and mesangial expansion
is particularly characteristic of FSGS, membranous and diabetic nephropathy, Alport’s
syndrome, and Denys-Drash syndrome (40). Mesangial expansion can contribute to
proteinuria through a mechanism that does not require podocyte depletion (as seen in this
study) (41). Additionally, both nephropathy and Alport’s syndrome are both characterized
by changes in collagen expression (42-44). Transcription of Col4a1 and A2 is coregulated
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diseases affecting collagen IV expression will be associated with changes in both α1(IV)
and α2(IV)) as seen in both the above disease and QLα12 mice (Figure 8). However,
Alport’s syndrome is caused by mutations in α3, α4, or α5(IV) collagen leading to
sustained α1 and α2(IV) expression whereas membranous nephropathy results from auto-
antibodies (46) that promote podocyte injury and subepithelial deposits.
Based on the time course of proteinuria and morphologic changes, we speculate that Gα12
modifies COL4 gene expression and the resulting basement membrane and endothelial
abnormalities accrue with time. However, whether these changes reflect age-dependent
effects or are the result of cumulative Gα12 activation will require additional study. Since
C57/B6 mice develop mild ultrastructural changes, cytokine activation and proteinuria with
age (as seen in some control mice), the phenotypic differences seen in the older mice with
Gα12 activation could represent indirect effects on cumulative age-related changes in this
mouse strain, or a cumulative time effect of Gα12 activation. Although the control mice do
develop mild changes with age, the dramatic differences seen in the age and sex matched
QLα12 mice strongly implicates the persistent Gα12 activation as the etiology.
Furthermore, the finding of up regulated COL4A1/2 seen with QLα12 expression in MDCK
cells (Supplemental figure 3) supports an important link, between Gα12 activation and
Col4A1/2 gene expression.
Although Gα12 stimulates TGFβ (20, 21) and could promote GS, we were unable to detect
increased TGFβ in either young or old mice (not shown). However, an alternative
mechanism is suggested by the increased number of subepithelial GBM membrane
projections (Fig. 5) similar to findings seen in DDR1 and integrin α2 knockout mice (47,
48). DDR1 is a tyrosine kinase receptor for collagen IV, and we previously showed that
Gα12 regulates α2β1 integrin signaling and attachment (17), thus suggesting that persistent
Gα12 activation might lead to podocyte changes in integrin signaling. The onset of
proteinuria is during adulthood and virtually all mice have proteinuria by mid-life (12-16m,
normal C57/B6 mouse life span ~3y (49)). With ageing, podocytes may accumulate damage
from a variety of sources including GPCR linked inflammatory and vasoactive mediators.
ROS, inflammation, and vascular changes occur in hypertensive and diabetic kidney disease,
and ROS directly activates Gα subunits (50). Based on these observations, we suggest that
this model of slowly progressive kidney disease will be valuable for understanding CKD
progression in humans. Consistent with GPCR pathways regulating age related kidney
damage, AT1 receptor knockout mice exhibit decreased oxidative damage and outlive their
wild-type littermates (51). The glomerular filtration rate declines with age, but it is unclear
whether this is part of normal ageing or represents injury from cumulative exposures. If
decreased renal function and GS occur through repetitive activation of podocyte signaling
pathways, it is tempting to speculate that inhibiting Gα12 pathways in podocytes may
provide new treatments to protect renal function and delay CKD progression.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. Endogenous Gα12 is expressed in normal mouse kidney
(A) Immunohistochemistry of normal mouse kidney demonstrates Gα12 expression in
glomeruli. Sections were probed with rabbit anti-Gα12 and visualized with Vectastain. Two
magnifications (20x and 40x) are shown (panel a, b). Negative controls were performed by
pre-incubating the antibody with excess blocking peptide (Gα12 + Pep). Kidney sections
using the blocked Gα12 antibody showed a significant reduction in staining (panel b, d). (B)
Immunoelectron microscopy shows Gα12 localizes to interdigitating foot processes (FP)
and major processes (MP). Immunogold labeling and electron microscopy were performed
as described in materials and methods. Magnification ~100,000x. Arrows denote gold
particles. Glomerular basement membrane (GBM), foot processes (FP), fenestrated
endothelium (E), and larger major processes (MP) are labeled.
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tFigure 2. Development of transgenic mice with podocyte specific expression of QLα12
(A) Schematic of targeting epitope tagged (EE) human QLα12 to podocytes. The floxed
LacZ/stop is driven by CMV promoter and Nphs-2 Podocin-Cre was used for podocyte
expression. (B) Transgenic mice show mosaic expression of LacZ. Control and
QLα12LacZ+/Cre+ mice at 2m of age (littermates) were stained for β-gal as describe in
materials and methods. Insets (c, d) show an individual glomerulus. (C) QLα12LacZ+/Cre+
mice express EE-tagged QLα12 in podocytes. Immunofluorescent staining was performed
on control (a) and QLα12LacZ+/Cre+ (b) mice using FITC conjugated goat anti-EE (shown in
green) and guinea pig anti-nephrin (Progen) and Cy3 secondary antibody (shown in red.)
(D) Activated Gα12 was pulled down from kidney lysates of QLα12LacZ+/Cre+ or thrombin
stimulated MDCK cells using GST-TPR or GST alone.
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tFigure 3. QLα12LacZ+/Cre+ mice develop of proteinuria with age
(A) Urine microalbumin/creatinine ratio in QLα12 mice is higher than in controls. Urine
from control and QLα12 mice were monitored every two months using a BCA Analyzer.
Albumin/Creatinine from individual control (○) and QLα12 (■) mice are shown. Lines
indicate median value (dashed, control; solid, QLα12). (B) Urine from QLα12 mice
contains high levels of albumin. Urine from 12 and 16 month QLα12 (QL) and littermate
control mice (C) was collected and analyzed by SDS-PAGE and Coommassie Blue staining.
The arrow denotes ~66kDa, the size of excreted albumin. Note that the 12m mice had more
concentrated urine (based on the non-specific low molecular weight bands). (C) QLα12
mice are more susceptible to LPS induced injury. Control (n=17) and QLα12 (n=21) mice
were injected with 10μg/g body weight LPS. Urine was collected 18h post injection and
analyzed for urine microalbumin/creatinine ratio a BCA Analyzer. Statistical analysis was
performed using two-way ANOVA followed by Bonferroni’s post hoc test (# p<0.001, *
p<0.0001)
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tFigure 4. Light micrographs show focal and segmental glomerulosclerosis in the juxtamedullary
region of older QLα12LacZ+/Cre+ mice
Representative light micrographs of murine juxtamedullary kidney cortex in control (top
row) and QLα12LacZ+/Cre+ (bottom row) mice aged 4.5, 13, and 24 m are shown (A,E)
Kidneys of mice aged <6 m, regardless of genotype, show no significant pathologic changes
in glomeruli, tubulointerstitium, or vasculature. (B, F) Kidney of QLα12LacZ+/Cre+ mice (F)
aged 12-18 months exhibit focal glomerulosclerosis involving juxtamedullary glomerulus
(arrow). The parenchyma is otherwise well-preserved. Age-matched controls (B) show no
significant pathologic changes. (C,D,G,H) Kidneys of QLα12LacZ+/Cre+ mice aged >18m
show focal global (G) and segmental (H) glomerulosclerosis involving multiple
juxtamedullary glomeruli (arrows), accompanied by focal interstitial mononuclear
inflammation. The non-lesional glomeruli (H; arrowhead) exhibit moderate mesangial
expansion by matrix and cells (*). Age-matched controls (C,D) show mild mesangial
expansion but no other cortical parenchymal lesions are apparent. PAS; bar = 100 microns
(left 3 columns), 50 microns (right column).
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tFigure 5. QLα12LacZ+/Cre+ develop foot process fusion and ultrastructural changes that worsen
with age
Transmission electron microscopy (EM) was performed on kidneys from control and
QLα12LacZ+/Cre+ mice at <6m(A, D), 12-18m (B, E), and >18 m (C, F) were analyzed in a
blindly and scored for severity of injury. Representative micrographs in control (top row)
and QLα12LacZ+/Cre+ (bottom row) mice aged 4, 14, and 23m are shown. At <6m, both
control (A) and QLα12LacZ+/Cre+ (D) show normal glomerular structure. By 12-18m, the
QLα12LacZ+/Cre+ mice (E) show more signs of endothelial injury (arrowhead) and
mesangial expansion (*) than controls (B). All of the oldest mice examined show significant
GBM thickening but the QLα12LacZ+/Cre+ (F) show increased development of subepithelial
basement membrane projections (◆) along the GBM. The podocytes have more foot
process effacement and irregularity (arrow) in addition to the mesangial expansion (*) and
endothelial injury arrowhead) seen the 12-18m mice compared with controls (C).
Boucher et al. Page 17
Lab Invest. Author manuscript; available in PMC 2012 November 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tFigure 6. QLα12LacZ+/Cre+ mice have normal numbers of podocytes
(A) WT-1 staining shows little podocyte apoptosis in both control and QLα12 mice. 24
fields and total >200 podocytes were counted for control and QLα12LacZ+/Cre+ mice.
TUNEL assays were performed on kidney sections from QLα12 and control mice 2-6 and
12-16m of age. Additionally, sections were probed for WT-1 and stained for DAPI. (B)
WT-1 quantification shows similar number of podocytes in both control and QLα12 mice.
The number of cells per glomeruli stained for both WT-1 and DAPI quantified for 100
glomeruli and averaged.
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tFigure 7. RhoA activity is not altered in QLα12LacZ+/Cre+ mice
(A) ELISA for activated RhoA was performed on young (2-6mo) and old (>12mo)
QLα12LacZ+/Cre+ and control mice. (B) Total RhoA did not change in QLα12LacZ+/Cre+
mice as they age. Western blot analysis was performed to examine total RhoA. Blots were
stripped and re-probed for GAPDH and ImageJ was used to determine RhoA/GAPDH
expression.
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tFigure 8. Collagen (α)IV is misregulated QLα12LacZ+/Cre+ mice
(A-B) Col4a1, Col4a2, and Col4a5 transcript expression are altered in QLα12LacZ+/Cre+
mice >12m of age. Various α chains of COL4 were examined in A (2-6 month) or B (>12
month) mice. Results were normalized to the 18S ribosomal subunit and graphed as relative
expression compared to non-targeting control (normalized to 1). n≥ 6 mice for each
experiment. (C) Immunofluorescent staining was performed on frozen kidney sections using
collagen antibodies [α1/2, Rockland; α3NC1 (mAb 8D1), α3α4α5NC1 (mAb 26-20), α5
(polyclonal)] (52) and Alexa488 anti-mouse or anti-rabbit secondary antibody.
Representative images are shown from QLα12LacZ+/Cre- and QLα12LacZ+/Cre+ mice 2-6
month or 12-16 month mice. Scale bar=100 microns
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